Cardiol Therapeutics (TSE:CRDL)
TSX:CRDL
Top Page
Cardiol Therapeutics
(TSX:CRDL)
Select Model
Select Model
Rating:48Neutral
Price Target:
C$2.00
▲(3.09% Upside)
Action:ReiteratedDate:04/08/26
The score is held back primarily by weak financial performance (pre-revenue, sizable ongoing losses, and sustained cash burn). Technicals are supportive with a positive trend, but overbought signals temper the benefit. Valuation provides limited support due to negative earnings and no dividend.
Positive Factors
Focused Therapeutic Pipeline
Cardiol's concentrated pipeline targets anti-inflammatory and anti-fibrotic therapies for cardiovascular disease using a proprietary CBD platform. This focused therapeutic niche and multiple programs increase strategic clarity and long-term potential for differentiated indications within an under-served area of cardiology.
Negative Factors
Pre-revenue Development Profile
Absence of product revenue means no commercial validation and prevents self-funding of operations. Over a multi-quarter horizon this maintains dependency on external capital to advance trials and scale, raising execution risk if financing environments tighten or trial timelines slip.
Read all positive and negative factors
Positive Factors
Negative Factors
Focused Therapeutic Pipeline
Cardiol's concentrated pipeline targets anti-inflammatory and anti-fibrotic therapies for cardiovascular disease using a proprietary CBD platform. This focused therapeutic niche and multiple programs increase strategic clarity and long-term potential for differentiated indications within an under-served area of cardiology.
Read all positive factors
Cardiol Therapeutics (CRDL) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$215.91M
Dividend YieldN/A
Average Volume (3M)136.50K
Price to Earnings (P/E)―
Beta (1Y)2.27
Revenue GrowthN/A
EPS Growth21.17%
CountryCA
Employees18
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.07
Shares Outstanding111,872,086
10 Day Avg. Volume86,077
30 Day Avg. Volume136,495
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)6.37
Price to Sales (P/S)0.00
P/FCF Ratio-4.77
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$11.76Price Target Upside506.42% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.42
Revenue Forecast (FY)N/A
Cardiol Therapeutics Business Overview & Revenue Model
Company Description
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product is CardiolRx, which is ...
How the Company Makes Money
null...
Cardiol Therapeutics Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
63
Positive
Cash Flow
22
Negative
| Breakdown | Mar 2026 | Mar 2025 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 78.76K |
| Gross Profit | 0.00 | -373.11K | -248.35K | -219.91K | 78.76K |
| EBITDA | -34.21M | -36.30M | -27.88M | -30.71M | -38.44M |
| Net Income | -33.82M | -36.68M | -28.13M | -11.52M | -24.72M |
Balance Sheet | |||||
| Total Assets | 23.62M | 31.86M | 36.70M | 62.03M | 87.88M |
| Cash, Cash Equivalents and Short-Term Investments | 21.42M | 30.58M | 34.93M | 59.47M | 83.90M |
| Total Debt | 125.52K | 158.53K | 158.53K | 72.87K | 117.58K |
| Total Liabilities | 5.74M | 7.14M | 8.45M | 9.83M | 11.64M |
| Stockholders Equity | 17.88M | 24.73M | 28.25M | 52.20M | 76.24M |
Cash Flow | |||||
| Free Cash Flow | -23.88M | -25.08M | -25.25K | -27.30M | -23.56M |
| Operating Cash Flow | -23.85M | -25.06M | -25.18K | -27.22M | -23.55M |
| Investing Cash Flow | -24.48K | -21.29K | -64.31K | -74.71K | -12.92K |
| Financing Cash Flow | 15.54M | 18.84M | -55.38K | -53.93K | 93.44M |
Cardiol Therapeutics Technical Analysis
Positive
1.94
Price Trends
1.45
Positive
1.43
Positive
1.54
Positive
Market Momentum
0.14
Negative
74.36
Negative
89.37
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:CRDL, the sentiment is Positive. The current price of 1.94 is above the 20-day moving average (MA) of 1.55, above the 50-day MA of 1.45, and above the 200-day MA of 1.54, indicating a bullish trend. The MACD of 0.14 indicates Negative momentum. The RSI at 74.36 is Negative, neither overbought nor oversold. The STOCH value of 89.37 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:CRDL.
Cardiol Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | C$478.32M | 10.05 | 24.23% | ― | 94.28% | 5.23% | |
71 Outperform | C$749.97M | -112.09 | -0.45% | ― | 18.70% | 88.31% | |
68 Neutral | C$114.34M | 294.90 | 0.87% | ― | 2.14% | -83.06% | |
55 Neutral | C$2.71B | 16.11 | -20.27% | ― | 8.68% | ― | |
54 Neutral | C$12.73M | -2.12 | -18.39% | ― | 24.30% | -68.60% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | C$215.91M | -3.37 | -218.48% | ― | ― | 21.17% |
* Healthcare Sector Average
TSE:CRDL
Cardiol Therapeutics
1.93
0.74
62.18%
TSE:BHC
Bausch Health Companies
7.31
0.45
6.56%
TSE:GUD
Knight Therapeutics
7.65
2.03
36.12%
TSE:CPH
Cipher Pharmaceuticals
18.92
7.72
68.93%
TSE:MPH
Medicure
1.22
0.59
93.65%
TSE:MDP
Medexus Pharmaceuticals Inc
3.54
1.50
73.53%
Cardiol Therapeutics Corporate Events
Business Operations and StrategyPrivate Placements and Financing
Cardiol Therapeutics Raises $14.85 Million in Bought-Deal Financing to Support Late-Stage Heart Disease Programs
Positive
Jan 23, 2026
Cardiol Therapeutics has closed a bought-deal private placement of 11,423,078 units at $1.30 per unit, including full exercise of the over-allotment option, raising gross proceeds of $14.85 million. Each unit comprises one common share and one-hal...
Business Operations and StrategyPrivate Placements and Financing
Cardiol Therapeutics Secures $13.5 Million Bought Deal Financing to Advance Heart Disease Programs
Positive
Jan 16, 2026
Cardiol Therapeutics has entered into a bought deal agreement with Canaccord Genuity Corp. for a private placement of 10,384,616 units at $1.30 per unit, raising gross proceeds of $13.5 million, with an option for the underwriter to purchase up to...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.